# Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

> **NCT02707588** · PHASE2 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 133 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02707588
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-18
- **Primary completion:** 2022-10
- **Final completion:** 2022-10-17
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707588, "Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02707588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*